1
|
de Leuze F, Havelange V, van Dievoet MA, Horsmans Y, Dahlqvist G. Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases. Acta Gastroenterol Belg 2023; 86:493-494. [PMID: 37814567 DOI: 10.51821/86.3.10755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/11/2023]
Abstract
Reactivation of the hepatitis B virus (HBV) with immunosuppressive status has been well established, mainly due to medications such as immunosuppressive therapy like cytotoxic chemotherapy, rituximab and biologic therapy, immunosuppression after solid and bone-marrow transplantation or long-term corticosteroids therapy. We report here two cases of HBV reactivation due to global hypogammaglobulinemia. Regular HBV serologic screening and PCR for HBV-DNA should be applied for each patient with primary immunosuppressive status and history of chronic HBV infection. The necessity of a preemptive treatment remains debated.
Collapse
Affiliation(s)
- F de Leuze
- Hepatogastroenterology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - V Havelange
- Hematology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - M-A van Dievoet
- Laboratory department, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Y Horsmans
- Hepatogastroenterology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - G Dahlqvist
- Hepatogastroenterology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| |
Collapse
|
2
|
Frezin J, Komuta M, Zech F, Annet L, Horsmans Y, Gigot JF, Jouret-Mourin A, Hubert C. Mucin-producing hepatic cystic neoplasms: an uncommon but challenging disease often misdiagnosed and mismanaged. Acta Chir Belg 2020; 120:6-15. [PMID: 30388391 DOI: 10.1080/00015458.2018.1532706] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background: Mucin-producing hepatic cystic neoplasms (MHCN) are uncommon and potentially malignant.Methods: Nine MHCN were encountered in our centre for over 32 years. Patients' clinical, biological, radiological and pathological features were reviewed. Lesions were classified into Mucinous Cystic Neoplasms (MCN) and Intraductal Papillary Neoplasms of the Bile duct (IPNB) (WHO 2010 classification).Results: Five MCN and 4 IPNB were reviewed. Serum and intracystic tumour markers were insufficient to diagnose malignancy. Complications were encountered in five out of nine patients (56%), mean symptom duration was 26 months (range: 1-132). Three patients were mismanaged pre-referral. Radiological features enabled preoperative diagnosis in eight out of nine patients (89%). Greater tumour size, unilocular lesion and mural nodularity indicated malignancy. Radical tumour excision was achieved in eight patients. One IPNB patient was misdiagnosed and underwent unroofing. For 103 months median follow-up, five out of six patients with benign tumours were alive and disease-free, whereas the misdiagnosed IPNB recurred with fatal malignant transformation seven years later. Among the three patients with malignancies (median follow-up: 77 months), two IPNB died, one from cancer recurrence and one from unrelated causes, whereas the malignant MCN was alive and disease-free.Conclusions: Appropriate MHCN diagnosis is crucial, yet it is often misdiagnosed and mismanaged. The prognosis after complete excision is favourable.
Collapse
Affiliation(s)
- J. Frezin
- Hepato-Biliary and Pancreatic Surgery, Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - M. Komuta
- Pathology Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - F. Zech
- Internal Medicine Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - L. Annet
- Medical Imaging Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - Y. Horsmans
- Gastro-Enterology and Hepatology Department, Cliniques universitairesSaint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - J. F. Gigot
- Hepato-Biliary and Pancreatic Surgery, Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - A. Jouret-Mourin
- Pathology Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| | - C. Hubert
- Hepato-Biliary and Pancreatic Surgery, Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium
| |
Collapse
|
3
|
Clarembeau F, Komuta M, Horsmans Y, Lanthier N. Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis. Acta Gastroenterol Belg 2019; 82:536-538. [PMID: 31950811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Chronic liver diseases such as hepatitis C or non-alcoholic fatty liver disease could be associated with insulin resistance, even in the absence of cirrhosis or significant fibrosis. In this report, we present the case of a patient who was diagnosed with primary biliary cholangitis and metabolic syndrome. Initial evaluation also revealed diabetes with elevated fasting plasma glucose and glycated hemoglobin. After eight weeks of treatment with ursodeoxycholic acid, a complete normalization of the hepatic biological tests was observed. A few months later, while body weight and abdominal perimeter remained stable, fasting blood glucose and glycated hemoglobin decreased significantly, compatible with diabetes disappearance. This finding supports the concept that the inflamed liver plays a major role in the pathogenesis of insulin resistance and diabetes occurrence in chronic liver diseases, including primary biliary cholangitis.
Collapse
Affiliation(s)
- F Clarembeau
- Service d'hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
- Laboratory of Hepatogastroenterology, Institut de recherche expérimentale et clinique, Université catholique de Louvain, Brussels, Belgium
| | - M Komuta
- Service d'Anatomie Pathologique, Cliniques universitaires SaintLuc, Université catholique de Louvain, Brussels, Belgium
| | - Y Horsmans
- Service d'hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
- Laboratory of Hepatogastroenterology, Institut de recherche expérimentale et clinique, Université catholique de Louvain, Brussels, Belgium
| | - N Lanthier
- Service d'hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
- Laboratory of Hepatogastroenterology, Institut de recherche expérimentale et clinique, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
4
|
Muyldermans G, Bielen R, Botterman R, Bourgeois S, Colle I, Deressa B, Devolder G, Horsmans Y, Hutse V, Lanthier N, Lasser L, Platteau S, Robaeys G, Suin V, Verhelst X, Van Vlierberghe H, Van Baelen L. Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis. Acta Gastroenterol Belg 2019; 82:479-485. [PMID: 31950802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
BACKGROUND AND STUDY AIMS Although multiple HCV prevalence studies were recently performed in the general population from Belgium, they suffer from a lack of geographical representativeness, an insufficient number of participants or a lack of inclusion of high prevalence groups. The aim of this study is to provide robust information on the HCV burden. METHODS Recently performed HCV prevalence studies in the general, adult population were included in this study, based on well-defined selection criteria. A meta-analysis was performed to estimate the seroprevalence, the prevalence of participants with viremia and the prevalence estimation for people with viremia which were unaware of their status. RESULTS Eight studies fulfilled the criteria for inclusion of the quantitative prevalence estimation. Based on the meta-analysis on these 8 studies, we estimated an HCV seroprevalence of 1.01% [95% CI : 0.66-1.42%], representing a total of 90,722 adult, HCV seropositives of which 64,412 individuals (0.71%) were confirmed seropositive. Based on the RNA presence, an estimated viremic prevalence of 0.33% [95% CI : 0.21-0.47 %] was determined, corresponding with 29,642 individuals. This is 46,0% of the true HCV seropositive residents. Further, based on the availability of patient information in 5 out of the 8 studies, a prevalence of 0.18% [95% CI : 0.07-0.33] representing 16,168 individuals from the adult Belgian population are unaware of their HCV status. CONCLUSIONS We believe that the quantitative measurement by the meta-analysis will be more reliable for their use in the design of a screening strategy or in the development of prevention campaigns as compared to the prevalence estimations performed at local level.
Collapse
Affiliation(s)
| | - R Bielen
- Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium
- Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium
| | - R Botterman
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium
| | - S Bourgeois
- Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium
| | - I Colle
- Department of Hepatology and Gastroenterology and Intensive Care Unit, Algemeen Stedelijk Ziekenhuis, Aalst, Belgium
| | - B Deressa
- Hepatogastroenterology Department, CHU Brugmann Brussels, Belgium
| | - G Devolder
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium
| | - Y Horsmans
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Belgium
| | - V Hutse
- Sciensano, Brussels, Belgium
| | - N Lanthier
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Belgium
| | - L Lasser
- Hepatogastroenterology Department, CHU Brugmann Brussels, Belgium
| | - S Platteau
- Department of Hepatology and Gastroenterology and Intensive Care Unit, Algemeen Stedelijk Ziekenhuis, Aalst, Belgium
| | - G Robaeys
- Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium
- Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium
- Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Herestraat 49, 3000 Leuven, Belgium
| | - V Suin
- Sciensano, Brussels, Belgium
| | - X Verhelst
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium
| | - H Van Vlierberghe
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium
| | | |
Collapse
|
5
|
Lanthier N, Ruiz-Moreno A, Dahlqvist G, Delire B, Stärkel P, Horsmans Y. Results of a screening campaign for hepatitis C viral infection in a Brussels hospital : do we need to go further? Acta Gastroenterol Belg 2019; 82:338. [PMID: 31314202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Affiliation(s)
- N Lanthier
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - A Ruiz-Moreno
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - G Dahlqvist
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - B Delire
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - P Stärkel
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Y Horsmans
- Service d'Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
6
|
Dahlqvist G, Horsmans Y, Komuta M, Coubeau L. Acute liver graft cellular rejection after interferon-free antiviral treatment for HCV infection. Is there a risk? A warning about three cases. Acta Gastroenterol Belg 2019; 82:53-56. [PMID: 30888754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
All patients transplanted for hepatitis C (HCV)- related cirrhosis will experience a recurrence of the viral disease on the liver graft with an accelerated course of the disease and a progression to advanced liver fibrosis in up to 50% of the patients at 5 years post-liver transplantation. HCV infection is a high risk for graft lost. We report here three cases of patients transplanted for hepatocellular carcinoma on HCV-related cirrhosis. All cases experienced an acute cellular rejection after the end of HCV therapy with direct acting antivirals (DAAs). We thus advocate for a close monitoring of tacrolimus and liver tests even a few months after the end of the treatment. Clinicians using DAAs after liver transplantation should be aware of the dynamics of tacrolimus levels during therapy and immunological changes that can occur even several weeks (or months) after the end of DAA treatment.
Collapse
Affiliation(s)
- G Dahlqvist
- Hepatogastroenterology Department Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Y Horsmans
- Hepatogastroenterology Department Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - M Komuta
- Anatomopathology Department Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - L Coubeau
- Abdominal Surgery Department Cliniques Universitaires Saint-Luc, Brussels, Belgium
| |
Collapse
|
7
|
Goeminne L, Sindano A, Horsmans Y, Kabamba Mukadi B. A43 Molecular epidemiology of hepatitis B virus in South Kivu, an eastern province of the Democratic Republic of Congo. Virus Evol 2018. [PMCID: PMC5905475 DOI: 10.1093/ve/vey010.042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- L Goeminne
- Institute of Experimental and Clinical Research (IREC), Pole de Microbiologie, Université Catholique de Louvain (UCL), Brussels, Belgium
| | - A Sindano
- Department of Internal Medicine, Université Catholique de Bukavu, Bukavu, DR Congo
- Gastroenterology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Bruxelles, Belgium
| | - Y Horsmans
- Gastroenterology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Bruxelles, Belgium
| | - B Kabamba Mukadi
- Institute of Experimental and Clinical Research (IREC), Pole de Microbiologie, Université Catholique de Louvain (UCL), Brussels, Belgium
| |
Collapse
|
8
|
Lanthier N, Etienne Q, Lebrun V, Poekes L, Horsmans Y, Leclercq I. MON-P069: Lipid, Fetuin-A and Macrophage Zonation in High Fat Diet FOZ-FOZ Mice with Non-Alcoholic Steatohepatitis. Clin Nutr 2017. [DOI: 10.1016/s0261-5614(17)31014-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Horsmans Y, Lambert M, Cochc E. Abstracts of the meeting of the Belgian Society of Internal Medicine (28 January 1989). Acta Clin Belg 2016. [DOI: 10.1080/17843286.1989.11717991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Jadoul M, Horsmans Y. Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure. Nephrol Dial Transplant 2014; 29:1108-10. [DOI: 10.1093/ndt/gfu047] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Mulkay JP, Bourgeois S, Lasser L, De Galocsy C, Tomasovic S, Horsmans Y, Van Vlierberghe H. Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in belgium: a sub-analysis of the PROPHESYS study. Acta Gastroenterol Belg 2014; 77:30-40. [PMID: 24761689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND AND STUDY AIMS PROPHESYS was a prospective, international cohort study of monoinfected, treatment-naive chronic hepatitis C patients treated with a combination of peginterferon alfa-2a or alfa-2b and ribavirin.It included worldwide 7,163 patients from 19 countries (including 384 patients from Belgium alone) and demonstrated that sustained virologic response rates in the real world were similar to those achieved in well-controlled clinical trials. The objective of this sub-analysis was to present an overview of the baseline characteristics, anti-hepatitis C drug treatment, and virologic responses of the patients treated in Belgium, infected with HCV genotype 1, 2, 3, or 4, and administered pegin-terferon alfa-2a. Moreover, the impact of ribavirin dosage on the response to treatment was studied. PATIENTS AND METHODS 356 patients were included in this sub-analysis. All variables were summarized using descriptive statistics. RESULTS Compared to the published data of the whole study population (1), the Belgian data presented some significant differences in terms of genotype distribution and response to treatment (e.g. lower prevalence of HCV genotype 1 infection, lower virologic response rates in HCV genotype 2 patients). Deviations from existing recommendations were identified (e.g. higher dose of ribavirin in HCV genotype 2 or 3 patients). Patients who received less than 80% of the target dose of ribavirin experienced a significantly weaker response to treatment. CONCLUSION This sub-analysis provided an interesting profile of the Belgian experience in the treatment of chronic hepatitis C.
Collapse
|
12
|
Ezgi Gulmez S, Lignot-Maleyran S, deVries C, Sturkenboom M, Perez-Gutthann S, Bénichou J, Bissoli F, Larrey D, Pageaux GP, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. SALT-I (Study of Acute Liver Transplant) : étude de l’insuffisance hépatique aiguë liée aux AINS dans des centres de transplantation hépatique européens. Rev Epidemiol Sante Publique 2011. [DOI: 10.1016/j.respe.2011.08.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Chen C, Fang M, Gao C, Stärkel P, Horsmans Y, Libert C. 462 Serum N-glycome biomarker for monitoring progression of DEN-induced hepatocellular carcinoma in rat. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71263-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
14
|
Abstract
IMPORTANCE OF THE FIELD The issue of age in cases of chronic hepatitis C (HCV) in the West is a major problem; the average age of patients with HCV is increasing and its prevalence increases with advancing age. AREAS COVERED IN THIS REVIEW This review is devoted to the analysis of the limited number of clinical studies performed to treat HCV in elderly patients. WHAT THE READER WILL GAIN The importance of the age factor is outlined in nearly all the studies done in the field. Advanced age is associated with a lower sustained virologic response (SVR) rate. Moreover, in elderly patients, these studies also tend to suggest that, before initiating an antiviral treatment, the physician should not only take into account the classical parameters associated with SVR but also the presence of co-morbidities and life expectancy. TAKE-HOME MESSAGES: Antiviral therapy should be used in selected elderly HCV patients with advanced fibrosis and more studies are required in this population to better define the parameters associated with SVR. As age is an important factor in the success of antiviral therapy, starting antiviral treatment at a young age should be favored.
Collapse
Affiliation(s)
- Y Horsmans
- Université catholique de Louvain, Cliniques Universitaires Saint-Luc, Department of Gastroenterology, 10, avenue Hippocrate, 1200 Brussels, Belgium.
| |
Collapse
|
15
|
Van Vlierberghe H, Adler M, Bastens B, Colle I, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Golstein P, Mulkay JP, Van Steenbergen W, Yap P, Nevens F, Denys AM, Brasseur JP. Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study. Acta Gastroenterol Belg 2010; 73:5-11. [PMID: 20458844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
BACKGROUND AND STUDY AIMS Large international clinical trials conducted in the past 5 years rapidly improved the treatment of chronic hepatitis C; however, it is unclear whether the advances seen in clinical trials are being paralleled by similar improvements in routine clinical practice. PegIntrust is a Belgian community-based trial evaluating the sustained virological response. PATIENTS AND METHODS Observational study of 219 patients receiving pegylated interferon alfa-2b (1.5 microg/kg/wk) and weight-based ribavirin (800-1200 mg/day) for 48 weeks. Primary study end point was sustained virological response (SVR), defined as undetectable HCV RNA 6 months after the completion of treatment. RESULTS In total, 108 patients (49.3 %) had undetectable HCV RNA at the end of therapy, 91 (41.6%) attaining SVR. Of the 111 patients without an end-of-treatment response, 28 were non-responders, and 21 had virological breakthrough. In total, 134 patients attained early virological response (EVR); 88 (65.7%) of those patients attained SVR. In contrast, 82 (96.5 %) of the 85 patients who did not attain EVR also did not attain SVR. Age, fibrosis score and baseline viral load were identified as important predictors of treatment outcome. The most frequently reported serious adverse events resulting in treatment discontinuation were anemia (n = 10), fatigue/asthenia/malaise (n = 6) and fever (n = 3). CONCLUSION Our data indicate that treatment of chronic hepatitis C with PEG-IFN alfa-2b plus weight-based ribavirin results in favourable treatment outcomes in a Belgian cohort of patients treated in community-based clinical practice.
Collapse
Affiliation(s)
- H Van Vlierberghe
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y, Michielsen P, Laureys A, Nevens F. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. Aliment Pharmacol Ther 2009; 30:352-63. [PMID: 19485978 DOI: 10.1111/j.1365-2036.2009.04052.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND The combination therapy of pegylated-interferon-alpha2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40-50% of naïve patients with genotype 1 and in around 80% of naïve patients with genotype 2 or 3. AIM To assess whether amantadine, added to the conventional combination therapy, could improve the treatment efficacy. METHODS In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) with amantadine (200 mg/daily); 314 patients (control group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) without amantadine. The duration of the treatment was 48 weeks for genotypes 1, 4, 5 and 6, and 24 weeks for genotypes 2 and 3. RESULTS There was no statistically significant difference between treatments groups for any of the variables tested for. Subgroups of patients likely to take advantage of the addition of amantadine were not identified. CONCLUSIONS This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients.
Collapse
|
17
|
Schneider-Merck T, Borbath I, Charette N, De Saeger C, Abarca J, Leclercq I, Horsmans Y, Stärkel P. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer 2009; 45:2050-60. [DOI: 10.1016/j.ejca.2009.04.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2008] [Accepted: 04/06/2009] [Indexed: 10/20/2022]
|
18
|
Froidure A, Horsmans Y, Lefebvre C. Multisystemic sarcoidosis associated with a second therapy for chronic hepatitis C. Acta Gastroenterol Belg 2009; 72:249-251. [PMID: 19637783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Hepatitis C virus (HCV) infection is a very common chronic infectious disease. Combined antiviral therapy including pegylated interferon and ribavirine is presently the standard treatment, with sustained viral response rate over 50%. Interferon induces the development of several autoimmune diseases. Some cases of induced sarcoidosis have been described (affecting mostly lungs, skin and eyes), both with standard and pegylated interferon. We report the case of an African woman, heterozygote for sickle cell anaemia mutation and for glucose-6-phosphate-deshydrogenase (G6PD) deficiency, who developed a multisystemic sarcoidosis (skin, lungs, liver, salivary and lachrymal glands, peripheral nerves), confirmed by biopsies, in the course of a second treatment with pegylated interferon and ribavirine for hepatitis C. The antiviral treatment was discontinued and all symptoms regressed spontaneously within some weeks.
Collapse
Affiliation(s)
- A Froidure
- Department of General Internal Medicine, St Luc University Hospital, Brussels, Belgium.
| | | | | |
Collapse
|
19
|
Stärkel P, Shindano T, Horsmans Y, Gigot JF, Fernandez-Tagarro M, Marin JJG, Monte MJ. Foetal 'flat' bile acids reappear during human liver regeneration after surgery. Eur J Clin Invest 2009; 39:58-64. [PMID: 19087130 DOI: 10.1111/j.1365-2362.2008.02059.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Changes in bile acid (BA) pool, such as the reappearance of typically foetal-type molecular species with a 'flat' structure at the steroid ring, occur during hepatocarcinogenesis, both in humans and rodents. Moreover flat-BAs also appear during rat liver regeneration. These changes can be detected in urine. The aim of the present study was to investigate whether flat-BAs also reappear during human liver regeneration, and whether this change correlates with the magnitude of liver resection. MATERIALS AND METHODS Patients undergoing partial hepatectomy were divided in two groups: major hepatectomy group (> 50% of hepatic tissue resection, n = 17) and minor hepatectomy group (< 50%, n = 13). BAs were extracted from serum and urine (collected over 24 h) and analysed by gas chromatography-mass spectrometry. Samples were obtained before surgery (day 0) and on the third and seventh days after hepatectomy. RESULTS In serum, total BAs significantly increased on day seven after hepatectomy, but only a moderate increase in flat-BA concentrations was observed. By contrast, urinary excretion of total as well as flat-BAs significantly increased at day three and day seven after hepatectomy. Moreover, the amount of flat-BAs excreted in urine during the first week after partial hepatectomy correlated with the magnitude of the resection. CONCLUSIONS Urinary BA output increases and flat-BAs reappear in urine during human liver regeneration. These results suggest that determination of BAs in urine may be an interesting parameter obtained by non-invasive techniques whose actual clinical value during human liver regeneration warrants further evaluation.
Collapse
Affiliation(s)
- P Stärkel
- Department of Gastroenterology, St. Luc University Hospital, Brussels, Belgium.
| | | | | | | | | | | | | |
Collapse
|
20
|
Garçon N, Van Mechelen M, Leroux-Roels G, Stanberry L, Osterhaus A, Heppner G, Kester K, Polhemus M, Horsmans Y, Cohen J. Vaccines Adjuvanted with Adjuvant Systems - from Concept to Clinical Evidence. Int J Infect Dis 2008. [DOI: 10.1016/j.ijid.2008.05.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
21
|
Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, Brenard R, Michielsen P, Goossens A, Bruckers L. Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. Acta Gastroenterol Belg 2008; 71:293-297. [PMID: 19198574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND AND STUDY AIMS The combination of Pegylated (PEG)interferon alpha-2b and ribavirin is considered to be the standard treatment for naïve chronic hepatitis C patients. Study aims are to evaluate the differences between standard interferon and PEG-interferon by conducting a multi-centre, controlled randomized trial comparing 3 groups. Group A : daily interferon alfa-2b at a dose of 4 MIU + ribavirin, Group B : PEG-interferon alfa-2b at a dose of 100 mcg/week + ribavirin; Group C: interferon alfa-2b at a dose of 3 MIU TIW + ribavirin PATIENTS AND METHODS Multicentrer, open label study including naïve chronic Hepatitis C Virus patients randomised in three groups with a ratio of 2:2:1. Group A: daily interferon alpha-2b (4 MIU s.c. for patients > 65 kg or 0.06 MIU/kg < 65 kg) and ribavirin, group B: PEG-interferon alpha-2b (100 microg s.c. weekly for patients > 65 kg or 1.5 microg/kg weekly for patients < 65 kg) and ribavirin and group C (reference arm) : interferon alpha-2b (3MIU s.c. TWI) and ribavirin. The duration of the treatment was 48 weeks for all 3 groups, with a 6 month follow-up period. 336 patients were enrolled in the study and included in the intention-to-treat analysis; 78 never started treatment (35 in group A, 28 in group B and 15 in group C): 101 in group A, 98 in group B and 59 in group C. RESULTS Demographic data, PCR results and reasons for early withdrawal have been statistically analysed. At baseline, the 3 groups did not show any statistical difference regarding age, gender, race, genotypes and METAVIR score. At week 24 on treatment, HCV ribonucleic acid RNA was undetectable in 87% in group A, in 79% in group B and in 69% in group C. At the end of treatment, 73% 74% and 58% respectively, had a negative PCR result. At week 24 of follow-up, these results were 71%, 64% and 48%, respectively. When comparing the efficacy of the daily interferon (+ ribavirin) and the PEG-interferon (+ ribavirin) regimen, no statistical difference was found (p = 0.32). In group A, 38% of drop-outs were due to adverse events compared to 37% in group B and 58% in group C. No statistical differences were observed regarding safety. CONCLUSION Daily weight based interferon alpha-2b dosing and PEG interferon alpha-2b weighed based dosing once weekly both in combination with Ribavirin offer the same efficacy and safety rates.
Collapse
Affiliation(s)
- Y Horsmans
- Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Wedemeyer H, Mazur W, Nevens F, Horsmans Y, Adler M, Blum H, Inglot M, Gerken G, Janczewska E, Roskams T, Desmet V, Renault J, Joos E, Coart E, Maertens G, De Winter H. 61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION. J Hepatol 2008. [DOI: 10.1016/s0168-8278(08)60063-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
23
|
Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat 2007; 14:523-36. [PMID: 17650286 DOI: 10.1111/j.1365-2893.2006.00831.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
According to the current guidelines, it is advised not to treat patients with mild chronic hepatitis C. However, discussions as to giving immediately a treatment (direct treatment) to these patients have started and the incremental cost-effectiveness ratio (ICER) of such strategy is still unknown. The aim of this study was to estimate, in the health care payer perspective, the ICER of a direct treatment of patients with mild chronic hepatitis C in comparison with the strategy of monitoring these patients and treat them when the disease will progress to the state of moderate chronic hepatitis. The treatment assessed was the current standard treatment composed of pegylated interferon alpha-2a and ribavirin. At the beginning of the study, patients were aged 45. Long-term economic and clinical outcomes over a 30-year period were predicted using a Markov simulation model. Data were obtained from published literature. Monte Carlo simulations were used to determine 95% confidence intervals of results. The ICER of a direct treatment with PEG IFN alpha-2a and ribavirin is 23,046 euro/QALY (CI 95% 3,882 euro-42,392 euro) for genotypes 1-4-5-6 and 4,631 euro/QALY (CI 95% 797 euro-7,881 euro) for genotypes 2-3. Sensitivity analysis shows that it is only in extreme circumstances related to the utilities that the ICER for genotypes 1-4-5-6 is unacceptably high for the society (>50,000 euro). Even though a direct treatment is more expensive, it gives the advantage of curing greater number of patients and of increasing quality-adjusted life-years (QALYs), implying that such strategy is generally cost-effective at a threshold of 50,000 euro/QALY.
Collapse
Affiliation(s)
- S Gerkens
- Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
24
|
Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 2007; 43:1755-63. [PMID: 17582756 DOI: 10.1016/j.ejca.2007.05.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2007] [Revised: 04/25/2007] [Accepted: 05/04/2007] [Indexed: 01/04/2023]
Abstract
Hepatocellular carcinoma (HCC) is increasing worldwide and is the fifth main cause of cancer-related death. HCC develops on a preneoplastic organ, the cirrhotic liver. Therefore, chemoprevention could play a role in the therapy of HCC. We evaluated the preventive effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the induction of early carcinogenic events. We monitored pre-neoplastic foci induced by a two-stage initiation/promotion model of hepatocarcinogenesis in rats, using diethylnitrosamine and acetylaminofluorene. Pioglitazone treatment was initiated the day after the first diethylnitrosamine injection. By quantitative morphometry and Western blot, we showed that pioglitazone significantly decreases the size of pre-neoplastic foci. Analysis of proliferation and apoptosis, assessed by immunohistochemistry, demonstrated decreased proliferation but no effect on cell death in rats treated with pioglitazone. These events were associated with an increased expression of the cyclin-dependent kinase inhibitor p27(kip1), compared to the non treated group. In conclusion, pioglitazone inhibits early carcinogenic transformation in a two-step rat model. As pioglitazone has a low toxicity profile, we believe it would be interesting to evaluate its effect in chemoprevention of HCC in humans in a clinical setting.
Collapse
Affiliation(s)
- I Borbath
- Gastroenterology Laboratory, Cliniques Universitaires St-Luc, Université catholique de Louvain, 10, avenue Hippocrate, 1200 Brussels, Belgium.
| | | | | | | | | |
Collapse
|
25
|
Danse E, Horsmans Y. [Calcified portal vein thrombosis in the follow-up of surgical portocaval shunt: Sonographic findings and differential diagnosis]. J Radiol 2006; 87:1696-9. [PMID: 17095965 DOI: 10.1016/s0221-0363(06)74149-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The case of a patient with large hepatic calcifications along the portal vascular network caused by long-standing portal vein thrombosis is presented. These calcifications appeared in extended portal thrombosis and were confirmed in follow-up for a surgical portocaval shunt related to portal hypertension. The differential diagnosis should distinguish these from hyperechoic patterns observed along the periportal vascular network, including intraductal biliary stones, portal venous gas, gas in the biliary tract, biliary comet tail artifacts, periportal fibrosis in parasitosis, and calcifications of the hepatic arteries.
Collapse
Affiliation(s)
- E Danse
- Département de Radiologie, Cliniques Universitaires St-Luc, Université Catholique de Louvain, av Hippocrate, 1200 Bruxelles, Belgique.
| | | |
Collapse
|
26
|
Abstract
Since the success rate of the antiviral treatment of chronic hepatitis C (HCV) is increasing, the knowledge of side effects due to this therapy must also improve. Among these side effects, depression and other neuro-psychiatric symptoms are among the most important. It must be outlined that conditions may exist before treatment in relation to the viral infection. However, pegylated interferon (IFN) administration is associated with a huge increase in the importance and the incidence of neuro-psychiatric symptoms. This has led several experts to claim that antiviral therapy should not be given to HCV patients having psychiatric contraindications. This last assertion seems to be disproved on the basis of results of recent clinical trials using selective serotonin reuptake inhibitors (SSRI). Pathogenesis of these neuro-psychiatric symptoms, however, remains unknown although the impact of IFN on glucocorticoid receptors and on serotonin 1A receptors is privileged. In conclusion, advances in HCV antiviral therapy and the comprehension and subsequent treatment of side effects induced by this therapy should allow us to treat more patients with greater success.
Collapse
Affiliation(s)
- Y Horsmans
- Department of Gastroenterology, Cliniques Universitaires Saint-Luc Université Catholique de Louvain, Belgium.
| |
Collapse
|
27
|
Abstract
AIM Peroxisome proliferator activated receptor gamma (PPARgamma) agonists have been shown to prevent hepatic fibrosis in rodents. We evaluated the therapeutic antifibrotic potential of the PPARgamma agonist pioglitazone on established hepatic fibrosis. METHODS Repeated injections of carbon tetrachloride (CCl4), a choline deficient diet, or bile duct ligation (BDL) were used to induce hepatic fibrosis in rats. Pioglitazone treatment was introduced at various time points. Therapeutic efficacy was assessed by comparison of the severity of hepatic fibrosis in pioglitazone treated versus untreated fibrotic controls. RESULTS When introduced after two weeks of CCl4, pioglitazone reduced hepatic fibrosis, OH proline content, hepatic mRNA expression of collagen type I, and profibrotic genes, as well as the number of activated alpha smooth muscle actin positive hepatic stellate cells, compared with rats receiving CCl4 only, with no significant change in necroinflammation. When pioglitazone treatment was initiated after five weeks of CCl4, no antifibrotic effect was observed. Similarly, pioglitazone was associated with a reduced severity of fibrosis induced by a choline deficient diet when introduced early, while delayed treatment with pioglitazone remained ineffective. In contrast, pioglitazone failed to interrupt progression of fibrosis due to BDL, irrespective of the timing of its administration. CONCLUSION In rats, the therapeutic antifibrotic efficacy of pioglitazone is limited and dependent on the type of injury, duration of disease, and/or the severity of fibrosis at the time of initiation of treatment.
Collapse
Affiliation(s)
- I A Leclercq
- Laboratoire de Gastroenterologie, Gastroenterology Unit, Université Catholique de Louvain, GAEN 53/79, Avenue Mounier, 53, B-1200 Brussels, Belgium.
| | | | | | | |
Collapse
|
28
|
Abstract
OBJECTIVE The administration of a fermentable dietary fibre (oligofructose) in rats increases satietogenic gut peptides and lowered spontaneous energy intake. The aim of the study was to assess the relevance of those effects of oligofructose on satiety and energy intake in humans. DESIGN Single-blinded, crossover, placebo-controlled design, pilot study. SUBJECTS Volunteers included five men and five women aged 21-39 years, BMI ranging from 18.5 to 27.4 kg/m(2), were randomly assigned as described below. INTERVENTIONS Subjects were included in two 2-week experimental phases during which they received either fibre (oligofructose (OFS)) or placebo (dextrine maltose (DM)); a 2-week washout period was included between crossover phases. In total, 8 g OFS or 8 g DM were ingested twice daily (16 g/day in total). Energy intake, hunger, satiety, fullness and prospective food consumption were assessed with analogue scales at the end of each experimental phase. RESULTS During breakfast, OFS significantly increases the satiety (P=0.04) without any difference on other sensations as compared to DM treatment periods. After lunch, no significant differences are observed between treatment period. At dinner, OFS significantly increases satiety (P=0.04), reduces hunger (P=0.04) and prospective food consumption (P=0.05). The energy intake at breakfast and lunch are significantly lower (P=0.01, 0.03, respectively) after OFS treatment than after DM treatment. Total energy intake per day is 5% lower during OFS than in DM period. CONCLUSION Oligofructose treatment increases satiety following breakfast and dinner, reduces hunger and prospective food consumption following dinner. This pilot study presents a rationale to propose oligofructose supplements in the management of food intake in overweight and obese patients.
Collapse
Affiliation(s)
- P D Cani
- Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Department of Pharmaceutical Sciences, Université catholique de Louvain, Brussels, Belgium
| | | | | | | |
Collapse
|
29
|
Abstract
A 57-year-old man presented with nephrotic syndrome associated with active HBV infection. Liver biopsy showed severe portal and moderate lobular inflammation, patchy necrosis, moderate fibrosis and several "ground glass" cells. Immunofluorescence microscopical view of the renal biopsy showed diffuse granular IgG deposits along the glomerular basement membrane, compatible with MN. As symptomatic therapy with ACE inhibitors did not improve the nephrotic syndrome, lamivudine 100 mg o.d. was initiated. HBV-DNA became undetectable after 10 weeks and seroconversion of HBeAg and HBsAg to anti-HBe and anti-HBs occurred after 2 additional months; proteinuria normalized subsequently. This observation documents for the first time in an adult the beneficial effect of lamivudine in glomerulonephritis related to HBV infection with HBV seroconversion and complete remission of the nephrotic syndrome.
Collapse
Affiliation(s)
- N Kanaan
- Department of Nephrology, Université catholique de Louvain, Cliniques Universitaires St. Luc, Brussels, Belgium.
| | | | | |
Collapse
|
30
|
Abstract
UNLABELLED Hypervitaminosis A-related liver toxicity may be severe and may even lead to cirrhosis. In the normal liver, vitamin A is stored in hepatic stellate cells (HSC), which are prone to becoming activated and acquiring a myofibroblast-like phenotype, producing large amounts of extracellular matrix. AIMS In order to assess the relationship between vitamin A intake, HSC activation and fibrosis, we studied nine liver biopsies from patients belonging to a well-characterized series of 41 patients with vitamin A hepatotoxicity. METHODS Fibrosis was underlined by Sirius-red staining, whereas activated HSC were immunohistochemically identified using an antibody against alpha smooth muscle actin. The volume density (Vv) of sinusoidal and total fibrosis and of sinusoidal and total activated HSC was quantified by the point-counting method. RESULTS Morphology ranged from HSC hypertrophy and hyperplasia as the sole features to severe architectural distortion. There was a significant positive correlation between Vv of perisinusoidal fibrosis and the daily consumption of vitamin A (P=0.004). CONCLUSION The close correlation between the severity of perisinusoidal fibrosis and the daily dose of the retinol intake suggests the existence of a dose-effect relationship.
Collapse
Affiliation(s)
- M-C Nollevaux
- Department of Pathology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
| | | | | | | | | | | | | |
Collapse
|
31
|
Adler M, Bastens B, Colle I, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Golstein P, Mulkay J, Nevens F, Van Steenbergen W, Yap P, Denys A, Brasseur J, Van Vlierberghe H. O.063 Effectiveness and tolerability of pegIntron® in combination with Rebetol® in real life: The pegIntrust study. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80068-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005; 59:723-6. [PMID: 15770222 DOI: 10.1038/sj.ejcn.1602127] [Citation(s) in RCA: 140] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE In experimental animals, recent results suggest that the addition of inulin-type fructans such as oligofructose (OFS) in the diet decreases triacylglycerol accumulation in the liver tissue. Therefore, we have investigated the effect of daily ingestion of OFS in seven patients with nonalcoholic steatohepatitis (NASH), confirmed by liver biopsies. DESIGN They received 16 g/day OFS or maltodextrine (placebo) for 8 weeks in a randomized double-blind crossover design. Energy intake, body composition, liver steatosis and blood parameters were analysed after 4 and 8 weeks of dietary supplementation. RESULTS Compared to placebo, OFS decreased significantly serum aminotransferases, aspartate aminotransferase after 8 weeks, and insulin level after 4 weeks, but this could not be related to significant effect on plasma lipids. CONCLUSION This pilot study supports the putative interest of OFS in the management of liver diseases associated with abnormal lipid accumulation in humans.
Collapse
Affiliation(s)
- C A Daubioul
- Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Université Catholique de Louvain, Brussels, Belgium
| | | | | | | | | |
Collapse
|
33
|
Laurent S, Stärkel P, Leclercq IA, Lambotte L, Maiter D, Horsmans Y. Molecular events associated with accelerated proliferative response in rat livers when partial hepatectomy is preceded by a sham operation. Eur J Clin Invest 2005; 35:140-7. [PMID: 15667586 DOI: 10.1111/j.1365-2362.2005.01449.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND When a sham operation is performed 6 h before partial hepatectomy (PH), the regenerative response is accelerated suggesting that sham operation itself contributes to cellular events leading to proliferation. MATERIALS AND METHODS In order to examine the mechanisms implicated in this acceleration, we compared the activation of several factors associated with the progression through the cell cycle at various times after PH and after PH preceded by sham operation (S6 h + PH). The effect of a single sham (S) and two combined sham operations (S6 h + S) was also examined. Nonoperated rats were used as controls (C). RESULTS The early factors NF-kappaB and Stat3 were activated after S6 h + PH and S6 h + S. C-jun expression was increased 0.5 h and 2 h after PH and 6 h after sham. There was no further increase in S6 h + PH and S6 h + S. In contrast, c-myc expression returned to baseline levels after S6 h and a new increase was observed 2 h after S6 h + PH but not after S6 h + S. P53 mRNA was significantly expressed 6 h after S6 h + PH, but at a level similar than that observed 6 and 12 h after PH alone. An earlier increase in c-Ha-ras mRNA and cyclin E protein was found in S6 h + PH, in comparison with PH alone. CONCLUSIONS The first divergent response between the two combined models involved c-myc expression. However, major differences related to the accelerated liver regenerative response observed after S6 h + PH were found at late time points associating an earlier expression of c-Ha-ras and nuclear cyclin E.
Collapse
Affiliation(s)
- S Laurent
- Department of Gastroenterology, Université Catholique de Louvain, 1200 Brussels, Belgium
| | | | | | | | | | | |
Collapse
|
34
|
Druez P, Cornet P, Rahier J, Horsmans Y. Spontaneous regression of inflammatory pseudotumor of the liver : a case report. Acta Gastroenterol Belg 2005; 68:101-3. [PMID: 15832596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- P Druez
- Department of Gastro-enterology, Hôpital St-Joseph 6060 GILLY, Belgium
| | | | | | | |
Collapse
|
35
|
Robaeys G, Buntinx F, Bottieau E, Bourgeois S, Brenard R, Colle I, De Bie J, Matheï C, Mulkay JP, Van Damme P, Van Ranst M, Verrando R, Michielsen P, Bourgeois N, Brenard R, de Galocsy C, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Reynaert H, Robaeys G, Sprengers D. Guidelines for the management of chronic hepatitis C in patients infected after substance use. Acta Gastroenterol Belg 2005; 68:38-45. [PMID: 15832586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- G Robaeys
- Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Schiepse Bos, 6, B-3600 Genk, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Lerut J, Matthys J, Lemaire J, Van Thuyne V, Ciccarelli O, Goffette P, Peeters A, Aunac S, Boddeus M, Carlier MA, Danse E, De Kock M, De Reyck C, Donataccio M, Geubel A, Gonze D, Goubau P, Latinne D, Laterre PF, Luts A, Cool G, Otte JB, Horsmans Y, Martinez J, Orlando G, Rahier J, Reding R, Reynaert M, Starkel P, Sempoux C, Talpe S, Van Obbergh L, Veyckemans F, Wallemacq P, Wittebolle X, Roggen F. Adult liver transplantation at UCL: update 2002. Acta Gastroenterol Belg 2004; 67:188-96. [PMID: 15285577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
The authors present the results of a single centre study of 587 liver transplants performed in 522 adults during the period 1984-2002. Results have improved significantly over time due to better pre-, peri- and post-transplant care. One, five, ten and fifteen year actuarial survivals for the whole patient group are 81.2; 69.8; 58.9 and 51.2%. The high incidence of de novo tumors (12.3%), of cardiovascular diseases (7.5%) and of end-stage renal function (3.6%) should be further incentives to tailor the immunosuppression to the individual patient and to direct the attention of the transplant physician to the long-term quality of life of the liver recipient.
Collapse
Affiliation(s)
- J Lerut
- Liver Transplant Program, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 1200 Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial. J Viral Hepat 2003; 10:460-6. [PMID: 14633181 DOI: 10.1046/j.1365-2893.2003.00466.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the hepatitis C virus (HCV) load and a better response rate. Naive chronically infected HCV patients (n = 454) were randomized into two arms to receive either induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily during a period of 8 weeks (arm A); or treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for a period of 8 weeks (arm B). After week 8, interferon treatment in both arms was 3 MU s.c. TIW for a total period of 12 months. In both arms, ribavirin (1000-1200 mg orally per day) was added at week 4. Induction treatment resulted in a higher virological response at week 8 of treatment (66%vs 47%; P < 0.01). However, response at the end of treatment and at 6 months follow-up was not different (53%vs 50%, 41%vs 33%). The occurrence of adverse events and the drop-out rate were similar in both arms. Although an early virological response is observed more frequently in the induction treatment, end of treatment response and sustained responses did not differ.
Collapse
Affiliation(s)
- H Van Vlierberghe
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium. hans.vanvlierberghe@rug,ac.be
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Van Beers B, Horsmans Y, Sempoux C. [Multidetector CT and MRI of benign liver tumors]. J Radiol 2003; 84:445-56; discussion 457-8. [PMID: 12844065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
With multidetector helical CT, the entire liver can be imaged rapidly with thin slices. High temporal and spatial resolution is important to improve multiphase examinations of the liver. The need to perform multiphase examinations to diagnose benign liver tumors should, however, be assessed by keeping in mind the risk of radiation and contrast-induced adverse events. MRI offers several advantages relative to CT. Excellent contrast resolution is obtained. Multiphase examinations can be performed in all patients. Reticuloendothelial contrast agents may be useful to characterize benign tumors. Several benign liver tumors, particularly hemangiomas and lesions of focal nodular hyperplasia, can be characterized with CT and MRI. Histologic examination is still needed to characterize some benign liver tumors.
Collapse
Affiliation(s)
- Be Van Beers
- Service d'imagerie médicale, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgique.
| | | | | |
Collapse
|
39
|
Michielsen P, Brenard R, Bourgeois N, De Galocsy C, Delwaide J, Henrion J, Horsmans Y, Nevens F, Reynaert H, Robaeys G, Sprengers D, Van Vlierberghe H. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol Belg 2003; 66:15-9. [PMID: 12812144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Affiliation(s)
- P Michielsen
- Department of Hepatogastroenterology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Eeckhoudt SL, Horsmans Y, Verbeeck RK. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 2002; 32:975-84. [PMID: 12487727 DOI: 10.1080/0049825021000012655] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
1. Midazolam is metabolized in the rat by CYP3A enzymes to 4-OH-midazolam (4-OH-MDZ) and 1'-OH-midazolam (1'-OH-MDZ). The induction of midazolam metabolism was studied in male Wistar rats treated with dexamethasone (50 mg kg(-1) day(-1)) during 4 days via the oral or intravenous routes. Microsomes were prepared from the liver and the proximal small intestine and in vitro metabolism of midazolam was determined. In addition, CYP3A1- and CYP3A2-like protein levels were measured by gel electrophoresis and immunoblotting. 2. The V(max)'s (mean SEM) for 4-OH-MDZ and 1'-OH-MDZ formation were much lower in intestinal (0.078 +/- 0.002 and 0.074 +/- 0.002 microM min(-1) mg(-1) protein, respectively) compared with hepatic microsomes prepared from the uninduced rat (0.870 +/- 0.007 and 0.310 +/- 0.020 microM min(-1) mg(-1) protein, respectively). Induction by oral or intravenous dexamethasone pretreatment led to significant increases in V(max) for 4-OH-MDZ and 1'-OH-MDZ by both intestinal and hepatic microsomes. Oral dexamethasone pretreatment via the oral route resulted in a more pronounced increase in V(max) compared with intravenous administration of the inducer. 3. CYP3A1 and CYP3A2 protein levels in liver microsomes were significantly increased following oral (3.7- and 3.2-fold, respectively) or intravenous (2.6- and 2.1-fold, respectively) pretreatment with dexamethasone. On the contrary, only oral dexamethasone pretreatment resulted in a significant change in intestinal CYP3A2-like protein (7.3-fold). A slight difference in the migration distance of the immunoreactive band for CYP3A2 was also observed for intestinal microsomes. 4. These results suggest that intestinal CYP3A enzymes in the rat differ from hepatic CYP3A1 and CYP3A2. They also demonstrate that systemic dexamethasone administration can induce intestinal microsome activity.
Collapse
Affiliation(s)
- S L Eeckhoudt
- Department of Pharmaceutical Sciences, Catholic University of Louvain, B-1200 Brussels, Belgium
| | | | | |
Collapse
|
41
|
Abstract
BACKGROUND The inhibition of thiopurine methyltransferase activity, one of the enzymes responsible for azathioprine metabolism, by aminosalicylates has been described in an in vitro study. This could result in a higher risk of bone marrow depression when using the two drugs together. AIM To investigate the in vivo interaction between azathioprine and aminosalicylates in quiescent Crohn's disease by measuring 6-thioguanine nucleotide levels, thiopurine methyltransferase activity and the plasma levels of the acetylated metabolite of 5-aminosalicylic acid. METHODS Sixteen patients taking a stable dose of azathioprine, plus sulfasalazine or mesalazine, were enrolled and completed the study. They were not taking any drugs interfering with azathioprine metabolism. Four visits every 4 weeks were held over a 3-month period. Aminosalicylate administration was withdrawn after the second visit. At each visit, the blood cell count, inflammatory parameters, levels of 6-thioguanine nucleotide and the acetylated metabolite of 5-aminosalicylic acid and thiopurine methyltransferase activity were determined. RESULTS After aminosalicylate withdrawal, mean 6-thioguanine nucleotide levels decreased significantly from 148 pmol (57-357 pmol) to 132 pmol (56-247 pmol) per 8 x 10(8) red blood cells (P=0.027), without significant changes in thiopurine methyltransferase activity or biological parameters. CONCLUSIONS This in vivo study favours the existence of an interaction between azathioprine and aminosalicylates through a mechanism which remains unclear. This drug-drug interaction should be taken into account when using azathioprine and aminosalicylates simultaneously.
Collapse
Affiliation(s)
- O Dewit
- Department of Gastroenterology, Catholic University of Louvain, Brussels, Belgium
| | | | | | | |
Collapse
|
42
|
Abstract
Quantification of hepatic perfusion parameters greatly contributes to the assessment of liver function. The purpose of this study was to describe and validate the use of dynamic MRI for the noninvasive assessment of hepatic perfusion parameters. The signal from a fast T(1)-weighted spoiled gradient-echo sequence preceded by a nonslice-selective 90 degrees pulse and a spoiler gradient was calibrated in vitro with tubes filled with various gadolinium concentrations. Dynamic images of the liver were obtained after intravenous bolus administration of 0.05 mmol/kg of Gd-DOTA in rabbits with normal liver function. Hepatic, aortic, and portal venous signal intensities were converted to Gd-DOTA concentrations according to the in vitro calibration curve and fitted with a dual-input one-compartmental model. With MRI, hepatic blood flow was 100 +/- 35 mL min(-1) 100 mL(-1), the arterial fraction 24 +/- 11%, the distribution volume 13.0 +/- 3.7%, and the mean transit time 8.9 +/- 4.1 sec. A linear relationship was observed between perfusion values obtained with MRI and with radiolabeled microspheres (r = 0.93 for hepatic blood flow [P < 0.001], r = 0.79 for arterial blood flow [P = 0.01], and r = 0.91 for portal blood flow [P < 0.001]). Our results indicate that hepatic perfusion parameters can be assessed with dynamic MRI and compartmental modeling.
Collapse
Affiliation(s)
- R Materne
- Department of Radiology, Université Catholique de Louvain, St-Luc University Hospital, Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
43
|
Van Vlierberghe H, Langlois M, Delanghe J, Horsmans Y, Michielsen P, Henrion J, Cartuyvels R, Billiet J, De Vos M, Leroux-Roels G. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001; 35:707-11. [PMID: 11738096 DOI: 10.1016/s0168-8278(01)00203-3] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND/AIMS Patients with genotypic Cys282Tyr homozygous hemochromatosis differ largely in phenotypic presentation. The HFE mutation on itself does not explain the different manifestations of hemochromatosis. We hypothesized that the genetic haptoglobin (Hp) polymorphism, because of its effect on iron metabolism, could be a modifying factor that influences the clinical presentation of hereditary hemochromatosis. METHODS In 167 Cys282Tyr homozygous hemochromatotic patients, the frequencies of Hp types (1-1, 2-1 and 2-2) and alleles (Hp1, Hp2) were compared with those in 918 healthy subjects. Clinical and laboratory indices of iron overload were incorporated in the analysis. RESULTS The Hp 2-2 type was overrepresented in the patient group (P<0.01). Male patients carrying Hp 2-2 had higher serum iron (P=0.003) and ferritin levels (P=0.03) than those with a Hp 1-1 or 2-1 type. The amount of iron removed with phlebotomy was also higher in Hp 2-2 patients (P=0.03). CONCLUSIONS The Hp 2-2 type is overrepresented among Cys282Tyr homozygous hemochromatotic patients. At diagnosis, iron overload was more pronounced in male patients carrying Hp 2-2. Our data suggest that Hp polymorphism affects iron metabolism in hereditary hemochromatosis.
Collapse
Affiliation(s)
- H Van Vlierberghe
- Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Stärkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001; 35:679-81. [PMID: 11690717 DOI: 10.1016/s0168-8278(01)00178-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND/AIMS Patients with end-stage liver disease due to chronic hepatitis B infection in whom a YMDD escape hepatitis B virus (HBV) mutant has emerged under lamivudine treatment are generally denied liver transplantation (OLT). METHODS We report the case of a male patient who was started on prophylactic treatment with lamivudine in the context of recurrent episodes of HBV reactivation during high dose immunosuppressive therapy for relapsing severe pulmonary sarcoidosis. RESULTS Following the emergence of a YMDD escape mutant virus under lamivudine treatment, he developed subacute liver failure requiring liver transplantation. The patient was treated with a combination of intravenous hepatitis B immune globulin (HBIG) which was started perioperatively and also continued lamivudine after OLT. Twelve months after OLT, there was no evidence of HBV reinfection of the liver graft with the use of HBIG and lamivudine. CONCLUSIONS This observation suggests that emergence of the YMDD mutation is not a contra-indication to OLT, providing adequate immunoprophylaxis using HBIG and lamivudine combination therapy.
Collapse
Affiliation(s)
- P Stärkel
- Department of Gastroenterology, Liver transplant program, St. Luc University Hospital, Université Catholique de Louvain, 1200 Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
45
|
Laterre PF, Horsmans Y. Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. Crit Care Med 2001; 29:1931-5. [PMID: 11588454 DOI: 10.1097/00003246-200110000-00014] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To compare intravenous omeprazole 40-mg single dose with 8 mg/hr after an 80-mg bolus injection on 24-hr intragastric pH in intensive care unit (ICU) ventilated patients. DESIGN Prospective, randomized crossover study. SETTING A 42-bed medicosurgical ICU in a university hospital PATIENTS Medicosurgical ventilated patients at risk of gastrointestinal bleeding. INTERVENTIONS After baseline determination of intragastric pH, patients were randomly allocated to have a 40-mg iv omeprazole bolus injection (arm I) or 80 mg bolus, followed by 8 mg/hr continuous infusion for 24 hrs (arm II). After a 24-hr washout period, the opposite regimen was given in a crossover design. Intragastric pH was determined at regular intervals during the treatment period. RESULTS In ten patients completing the protocol, the intragastric pH was similar for the two regimens for the first 12 hrs. The area under the pH curve was 5.51 +/- 0.48 for arm I compared with 6.02 +/- 0.33 for arm II (NS). Time to reach a pH of 4 or 6 was not significantly different for the two regimens. Time spent with a pH greater than 4 and 6 for the first 12 hrs was 10.11 +/- 1.14 and 8.31 +/- 1.16 hrs vs. 10.11 +/- 0.75 and 7.43 +/- 1.19 hrs for arm I and arm II, respectively (NS). When the first 24 hrs are considered, the area under the pH curve was 5.17 +/- 0.49 for arm I vs. 6.36 +/- 0.25 for arm II (p <.05). Time spent with a pH greater than 4 and 6 was 17.2 +/- 2.4 hrs and 12.63 +/- 2.22 vs. 23 +/- 0.41 and 19.48 +/- 1.63 in arm I and arm II, respectively (p <.05 and.01). An intragastric pH above 6 for all determinations was only observed in arm II. CONCLUSIONS In critically ill patients, intravenous omeprazole 40 mg single dose is as effective as 8 mg/hr after an 80-mg bolus injection on mean intragastric pH, time spent with a pH greater than 4 and 6, but only for the first 12 hrs. If an intragastric pH greater than 6 has to be maintained for 24 hrs in all patients, an 80-mg bolus followed by 8 mg/hr iv omeprazole is to be given. Our data suggest that in several critically ill patients, a single 40-mg iv omeprazole bolus injection may be able to achieve stress ulcer prophylaxis and that 40 mg twice daily should be compared with 8 mg/hr after an 80-mg bolus injection in bleeding ulcers.
Collapse
Affiliation(s)
- P F Laterre
- Department of Critical Care Medicine, Cliniques Universitaires St. Luc, Brussels, Belgium.
| | | |
Collapse
|
46
|
Laurent S, Otsuka M, De Saeger C, Maiter D, Lambotte L, Horsmans Y. Expression of presumed specific early and late factors associated with liver regeneration in different rat surgical models. J Transl Med 2001; 81:1299-307. [PMID: 11555677 DOI: 10.1038/labinvest.3780343] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Experiments performed on the portal branch ligation (PBL) model indicate that early changes observed after surgery are not related to the regenerative process because they also occur in atrophying lobes. To further confirm the lack of specificity of the early events and to exclude the influence of circulatory factors released by proliferating lobes on their occurrence, we investigated this response after sham operation (SO) and portacaval shunt (PCS), a model characterized by liver atrophy. We also attempted to determine expression of later events associated specifically with regeneration, ie, expression of p53 or c-Ha-ras, or inhibition of proliferation, ie, interleukin-1beta (IL-1beta) and transforming growth factor-beta1 (TGF-beta1) after partial (PH) and temporary partial (TPH) hepatectomy, SO and PCS. Nuclear factor-kappaB (NF-kappaB) and signal transducer and activator of transcription 3 (STAT3) DNA binding were assessed by electrophoretic mobility shift assay (EMSA), interleukin-6 (IL-6) mRNA by reverse transcription-polymerase chain reaction (RT-PCR), c-myc and c-jun mRNAs by Northern blot analysis at 0.5 and 2 hours, p53 and c-Ha-ras mRNAs by Northern blot analysis at 8 and 24 hours, and IL-1beta and TGF-beta1 by RT-PCR at 24 hours. The early response including an increase of NF-kappaB, STAT3, IL-6, and immediate-early genes expression was present after PH, PCS, and SO. In SO, slight differences were observed in comparison with PH: no NF-kappaB p65/p50 DNA binding was observed, only three of six SO rats were positive for IL-6, and immediate-early genes induction showed differences in the intensity of the response. At later times, p53 mRNA increased at 8 hours after PH and TPH, c-Ha-ras mRNA at 24 hours after PH, and IL-1beta mRNA at 24 hours after PCS. Early events are not specifically associated with the reduction of liver mass or with the regenerative process, are not predictive of future cell fate, and are most likely related to surgical stress. p53 and c-Ha-ras induction is closely associated with cell cycle progression whereas IL-1beta, but not TGF-beta1, appears to be one of the negative growth regulators that might play an important role in atrophy.
Collapse
Affiliation(s)
- S Laurent
- Gastroenterology Laboratories, Université Catholique de Louvain, Brussels, Belgium
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
We report on a patient who presented, on 2 occasions at one-year interval after a treatment with the amoxicillin-clavulanic acid association, a clinical and biological picture in keeping with the diagnosis of immuno-allergic hepatocellular hepatitis. On liver biopsies, the most characteristic finding was portal and lobular eosinophilic infiltration without cholestasis and biliary ducts damage.
Collapse
Affiliation(s)
- F Breuskin
- Division of General Internal Medicine, Saint-Luc University Hospital Avenue, Hippocrate 10, B-1200 Brussels-Belgium
| | | | | | | |
Collapse
|
48
|
Stärkel P, Lambotte L, Sempoux C, De Saeger C, Saliez A, Maiter D, Horsmans Y. After portal branch ligation in the rat, cellular proliferation is associated with selective induction of c-Ha-ras, p53, cyclin E, and Cdk2. Gut 2001; 49:119-30. [PMID: 11413120 PMCID: PMC1728374 DOI: 10.1136/gut.49.1.119] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Abstract
BACKGROUND In liver regeneration after portal branch ligation we previously showed that early cellular changes are observed in both the proliferating and atrophying liver lobes. They are therefore not indicative of future proliferative response. In this study we attempted to define precisely, in the same model, the time at which the cellular processes diverge between the lobes by measuring various parameters associated with cellular proliferation. We also investigated the possible role of inhibitors of cell proliferation in the absence of progression towards the S phase in the atrophying lobes. AIMS Expression of p53, c-Ha-ras, cyclin E, cyclin dependent kinase (Cdk2), transforming growth factor (TGF)-beta, and interleukin (IL)-1alpha and IL-1beta were assessed in relation to their potential role in proliferating and atrophying cellular phenomenons. METHODS Immunohistochemistry, northern blotting, western blotting, and reverse transcription-polymerase chain reaction were performed, mainly at time points corresponding to mid-G1/S phase progression (8-24 hours after surgery). RESULTS The common and thus most likely non-specific response was still evident 5-8 hours after surgery and included an increase in IL-1 mRNA as well as p53 and cyclin E proteins. From 12 hours onwards, p53, c-Ha-ras, cyclin E, and Cdk2 were selectively induced in proliferating lobes whereas IL-1beta was predominantly activated in atrophying lobes. No changes in TGF-beta or IL-1alpha expression were observed at the same time points in any of the liver lobes. CONCLUSIONS The initial response to portal branch ligation and thus probably to partial hepatectomy seems to be non-specific for at least eight hours. Thereafter, p53, c-Ha-ras, cyclin E, and Cdk2 seem to drive cellular proliferation while IL-1beta is associated with cellular atrophy. In contrast, TGF-beta and IL-1alpha do not seem to play a role in determining the commitment of cells towards atrophy or proliferation.
Collapse
Affiliation(s)
- P Stärkel
- Laboratories of Gastroenterology, Université Catholique de Louvain, 1200 Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
49
|
Eeckhoudt SL, Desager JP, Robert AR, Leclercq I, Verbeeck RK, Horsmans Y. Midazolam and cortisol metabolism before and after CYP3A induction in humans. Int J Clin Pharmacol Ther 2001; 39:293-9. [PMID: 11471773 DOI: 10.5414/cpp39293] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION CYP3A is responsible for the metabolism of numerous endogenous and exogenous compounds. Several substrates of CYP3A have been investigated to assess the CYP3A-metabolizing capacity of an individual in an attempt to predict the rate of metabolism of other CYP3A substrates. Two such tests of CYP3A activity are the midazolam plasma clearance after its intravenous administration and the 6beta-OH cortisol urinary ratio. Possible correlations between these 2 tests were investigated before and after treatment with rifampin in a group of healthy volunteers. METHODS Pharmacokinetic parameters of midazolam and 6beta-OH cortisol urinary ratio were evaluated in 8 volunteers before and after 6 days treatment with rifampin, a potent inducer of CYP3A, and after cessation of rifampin treatment. RESULTS Midazolam systemic clearance and the 6beta-OH cortisol urinary ratio were significantly higher at Days 7 and 10 than at Day 0. There was a strong positive correlation between these 2 parameters (r = 0.70, p < 0.001). In contrast, no correlation was observed between the ratio of the AUCs of 1'-OH midazolam vs. midazolam (AUC0-1(1'-OH)/AUC0-t(MDZ)) or the ratio of plasma concentration of 1'-OH midazolam vs. midazolam (C30 min(1'-OH)/C30 min(MDZ)) and the 6beta-OH cortisol urinary ratio (r = 0.05, p = 0.82; r = 0.04, p = 0.88, respectively). Considering only data obtained before or after treatment with rifampin, however, no correlation was observed between midazolam systemic clearance and the 6beta-OH cortisol urinary ratio. CONCLUSIONS These data demonstrate that there is a strong positive correlation between systemic midazolam clearance and 6beta-OH cortisol urinary ratio before and after induction. This suggests that the 6beta-OH cortisol urinary ratio test is a non-invasive alternative to the use of systemic midazolam clearance for monitoring the time-course of CYP3A induction.
Collapse
Affiliation(s)
- S L Eeckhoudt
- Unité de Pharmacocinétique, Métabolisme, Nutrition et Toxicologie, Ecole de Santé Publique, Université catholique de Louvain, Brussels, Belgium
| | | | | | | | | | | |
Collapse
|
50
|
Vanhulle VP, Martiat GA, Verbeeck RK, Horsmans Y, Calderon PB, Eeckhoudt SL, Taper HS, Delzenne N. Cryopreservation of rat precision-cut liver slices by ultrarapid freezing: influence on phase I and II metabolism and on cell viability upon incubation for 24 hours. Life Sci 2001; 68:2391-403. [PMID: 11350010 DOI: 10.1016/s0024-3205(01)01031-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Several cryopreservation methods for precision-cut rat liver slices (PCLS) have been proposed, allowing a short-term (a few hours) maintainance of viability and functionality upon thawing. The aim of the present study was to test the metabolic capacity of PCLS cryopreserved by an ultrarapid method. The biotransformation of paracetamol to its glucuronide and sulfate conjugates and of midazolam to its hydroxylated metabolites was studied in thawed PCLS incubated for 24 hours at 37 degrees C in Williams' medium E. In addition, protein levels of the key enzymes involved in these metabolic reactions, i.e. UGT1A1, ST1A1, CYP2E1 and CYP3A2 were determinated. In addition, biological markers of cell function (ATP and glycogen levels) and toxicity (LDH leakage in the medium) were also measured. Compared to controls (non cryopreserved PCLS), CYP3A2 activity and content and CYP2E1 content were maintained at the same level all along the incubation, whereas paracetamol glucuronidation and sulfation dropped to 24 and 21% of the control value, respectively, immediately after thawing. Freezing-thawing conditions also modified cell functionality, leading to a lower intracellular ATP and glycogen content, and an increase in cell lysis, as shown by LDH released in the medium. The results of this study suggest that cryopreserved PCLS are able to maintain some phase I activities for 24 hours after thawing whereas some phase II metabolic capacities are not maintained.
Collapse
Affiliation(s)
- V P Vanhulle
- Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Université Catholique de Louvain, Brussels, Belgium
| | | | | | | | | | | | | | | |
Collapse
|